Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Omnicom Group Inc. (OMC) vs Revvity Inc (RVTY) Price & Performance

Omnicom Group Inc.Trade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Omnicom Group Inc. vs Revvity Inc — how do they compare? Omnicom Group Inc. trades at $78.55 (market cap $22.26B), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays the higher dividend (3.94%). Which is the better fit depends on your goals.

OMCRVTY
Market Cap
$22.26B$14.18B
Sector
MediaTechnology
52-Week High
$88.94$130.94
52-Week Low
$67.27$82.26
Enterprise Value
$30.33B$16.50B
Dividend Yield
3.94%0.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Omnicom Group Inc.

Omnicom Group (OMC) trades at $81.13, down 1.8% on the day, with a bearish technical outlook and mixed quarterly earnings performance. The company reported strong revenue growth to $17.27 billion in 2025 but posted a net loss of $54.5 million due to acquisition costs. Analyst consensus remains cautious with a 'Hold' rating despite a $96.50 price target representing 19% upside potential. Recent leadership transitions and media agency consolidation signal strategic repositioning amid challenging market conditions.

OMC presents a value opportunity with attractive valuation multiples (P/S: 0.91x, P/B: 2.3x) and a 4% dividend yield, but faces integration risks from the Interpublic acquisition and margin pressure. The stock's near-term trajectory depends on successful cost synergies and organic growth acceleration beyond current 6.1% levels. Debt levels have increased substantially post-acquisition, requiring careful monitoring of cash flow generation.

Revvity Inc

RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.

Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Omnicom Group Inc.

Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.

Read more on OMC

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY